01—Abstract
Summary
Summary of the 10-K filed February 11, 2021. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported total revenues of $987.5 milliona for fiscal 2020, up from $967.8 million in 2019, and net income of $111.8 million, or $0.35 per diluted share, compared with $321.0 million, or $1.02 per diluted share, in 2019.
Net product revenues from CABOMETYX and COMETRIQ declined to $741.6 millionb from $760.0 million, which the company attributes in part to COVID-19 reducing prescriptions. Growth in total revenue came from license revenues of $167.3 million and collaboration services revenues of $78.7 million, which rose from $41.9 million. Research and development expenses rose to $547.9 million from $337.0 million, and selling, general and administrative expenses rose to $293.4 million from $228.2 million, reflecting expanded clinical trials and business development.
Cash and investments totaled $1.54 billionc at year-end. The company's near-term growth depends on CABOMETYX, which the FDA approved in combination with OPDIVO as a first-line treatment for advanced renal cell carcinoma on January 22, 2021. Exelixis also reported positive phase 3 results for COSMIC-311 in differentiated thyroid cancer, with a hazard ratio of 0.22, and disclosed that the EXAMINER trial did not meet its primary endpoint.
The company is defending patent infringement lawsuits against MSN Pharmaceuticals over a generic version of CABOMETYX, with a bench trial scheduled for May 2022. The filing states the company expects net product revenues to increase in 2021 and license revenues to decrease, and it projects research and development and selling, general and administrative expenses to continue rising. The filing describes a broad oncology pipeline of more than 100 ongoing or planned cabozantinib trials, along with early-stage programs XL092 and XL102 and several research collaborations for antibody-drug conjugates.
Revenue concentration is significant: Ipsen accounted for 15%d of total revenues in 2020, and three pharmacy and distribution affiliates accounted for 11% to 14% each. Investors should weigh the company's reliance on a single franchise, its exposure to generic competition, and the timing of milestone-driven revenue.
02—Key points
Key Highlights
- Total revenues were $987.5 million in 2020, up from $967.8 million in 2019, while net product revenues declined to $741.6 million from $760.0 million.
- Net income was $111.8 million, or $0.35 per diluted share, compared with $321.0 million, or $1.02 per diluted share, in 2019.
- FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment for advanced RCC on January 22, 2021.
- COSMIC-311 in differentiated thyroid cancer met its co-primary endpoint of PFS, with a hazard ratio of 0.22; EXAMINER did not meet its primary endpoint.
- Research and development expenses rose to $547.9 million from $337.0 million, and SG&A expenses rose to $293.4 million from $228.2 million.
- Cash and investments totaled $1.54 billion at December 31, 2020, up from $1.39 billion a year earlier.
- Patent litigation against MSN Pharmaceuticals over a generic version of CABOMETYX has a bench trial scheduled for May 2022; Ipsen accounted for 15% of 2020 total revenues.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2021, Exelixis kept $0.16.
- Revenue$1.43B100.0%
- Cost of revenue−$52.9M3.7%
- Gross profit$1.38B96.3%
- Operating costs−$1.10B76.3%
- Operating income$286.7M20.0%
- Interest, other & tax−$55.6M3.9%
- Net income$231.1M16.1%
Where FY2021 revenue went
$1.43B- R&D: $693.7M, 48% of revenue
- SG&A: $401.7M, 28% of revenue
- Net income: $231.1M, 16% of revenue
- Cost of revenue: $52.9M, 3.7% of revenue
- Interest, other & tax: $55.6M, 3.9% of revenue
Kept 16% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 11, 2021Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $1.43B$967.77M | +48.3% |
| Cost of Revenue | $52.87M$33.10M | +59.8% |
| Gross Profit | $1.38B$934.68M | +47.9% |
| R&D Expenses | $693.72M$336.96M | +105.9% |
| SG&A Expenses | $401.71M$228.24M | +76.0% |
| Operating Expenses | $1.15B$598.30M | +91.9% |
| Operating Income | $286.67M$369.47M | −22.4% |
| Net Income | $231.10M$321.01M | −28.0% |
| EPS (Basic) | $0.73$1.06 | −31.1% |
| EPS (Diluted) | $0.72$1.02 | −29.4% |
| Shares Outstanding (Basic) | 314.88M302.58M | +4.1% |
| Shares Outstanding (Diluted) | 322.36M315.01M | +2.3% |
05—Questions
Frequently Asked Questions
Why did net product revenues decline in 2020 even though total revenues grew?
Net product revenues fell to $741.6 million from $760.0 million, mainly due to lower CABOMETYX sales volume tied to fewer prescriptions, which the company partly attributes to COVID-19. Total revenues rose to $987.5 million because license revenues increased to $167.3 million and collaboration services revenues increased to $78.7 million, driven by milestone and reimbursement income from partners.
What drove the drop in net income in 2020?
Net income fell to $111.8 million from $321.0 million. Operating expenses rose to $877.5 million from $598.3 million, led by research and development expenses of $547.9 million, up from $337.0 million, and SG&A expenses of $293.4 million, up from $228.2 million. The filing also notes a net loss in the third quarter of 2020, primarily due to higher clinical trial, license and personnel costs.
What is the near-term catalyst for CABOMETYX?
The FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment for advanced RCC on January 22, 2021, and the company and BMS commenced the commercial launch. The company expects this to increase unit sales and selling price in 2021, and it expects net product revenues to rise over 2020.
What legal risk could affect future revenue?
MSN Pharmaceuticals filed an ANDA for a generic version of CABOMETYX tablets and asserted Paragraph IV certifications. Exelixis filed two patent infringement lawsuits, which were consolidated, and a bench trial is scheduled for May 2022. The filing states that an early generic sale could significantly decrease U.S. CABOMETYX revenues.
How concentrated is the company's revenue?
In 2020, Ipsen accounted for 15% of total revenues, affiliates of CVS Health for 14%, affiliates of McKesson for 12%, affiliates of Optum Specialty Pharmacy for 11%, and affiliates of AmerisourceBergen for 11%. The company operates as a single business segment with operations solely in the U.S.
06—Continue